Who is sponsoring NCT00048620?

NCT00048620 is sponsored by BioMarin Pharmaceutical.

What condition does NCT00048620 study?

NCT00048620 studies Mucopolysaccharidosis VI.

What drugs are being tested in NCT00048620?

Interventions: N-acetylgalactosamine 4-sulfatase.

What is the status of NCT00048620?

NCT00048620 is currently COMPLETED.

Last reviewed 2006-11-02 · How we verify

Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

NCT00048620 Phase 1 COMPLETED

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.

Details

Lead sponsor	BioMarin Pharmaceutical
Phase	Phase 1
Status	COMPLETED
Start date	2000-09
Completion	2005-11

Conditions

Mucopolysaccharidosis VI

Interventions

N-acetylgalactosamine 4-sulfatase

Primary outcomes

Lysosomal storage disease

Countries

United States